Singapur - engleski - HSA (Health Sciences Authority)

roche singapore pte. ltd. - tocilizumab - infusion, solution concentrate - 20mg/ml - tocilizumab 20mg/ml

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - tocilizumab 20mg;  ;  ;   - concentrate for infusion - 20 mg/ml - active: tocilizumab 20mg       excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection - actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients: · in combination with methotrexate (mtx) in those not previously treated with mtx. · in combination with methotrexate (mtx) or other non-biological disease-modifying anti-rheumatic drugs (dmards) in case of either an inadequate response or intolerance to previous therapy with one or more dmards; or · as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra has been shown to inhibit the progression of joint damage in adults, as measured by x-ray, when given in combination with methotrexate

Europska Unija - engleski - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosuppressants - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.- the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx.tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Kanada - engleski - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 80mg - tocilizumab 80mg - disease-modifying antirheumatic agents

Kanada - engleski - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 200mg - tocilizumab 200mg - disease-modifying antirheumatic agents

Kanada - engleski - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 400mg - tocilizumab 400mg - disease-modifying antirheumatic agents